Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 1950-1961

  Tang, Ruihan ^a   Yang, Guang ^a,b   Zhang, Shenghong ^a   Wu, Changyou ^c   Chen, Minhu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Inflammatory bowel diseases; IRF1; Osteopontin; TNF

Indexed keywords

C REACTIVE PROTEIN; DEXTRAN SULFATE; INTERFERON REGULATORY FACTOR 1; LUCIFERASE; OSTEOPONTIN; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; IRF1 PROTEIN, HUMAN; MESSENGER RNA; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CACO 2 CELL LINE; CHILD; CHROMATIN IMMUNOPRECIPITATION; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE DURATION; DISEASE SEVERITY; DOWN REGULATION; ENDOSCOPIC BIOPSY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED; COLITIS; COLITIS, ULCERATIVE; COMPARATIVE STUDY; DRUG EFFECTS; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW UP; GENETICS; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CACO-2 CELLS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CHROMATIN IMMUNOPRECIPITATION; COLITIS; COLITIS, ULCERATIVE; CROHN DISEASE; DEXTRAN SULFATE; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON REGULATORY FACTOR-1; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84925688608     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000192     Document Type: Article

References (43)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
2. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
3. Wang J, Fu YX. Tumor necrosis factor family members and inflammatory bowel disease. Immunol Rev. 2005;204:144-155.
4. Frey MR, Edelblum KL, Mullane MT, et al. The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology. 2009;136:217-226.
5. Hilliard VC, Frey MR, Dempsey PJ, et al. TNF-alpha converting enzymemediated ErbB4 transactivation by TNF promotes colonic epithelial cell survival. Am J Physiol Gastrointest Liver Physiol. 2011;301:G338-G346.
6. Avdagic N, Babic N, Seremet M, et al. Tumor necrosis factor-alpha serum level in assessment of disease activity in inflammatory bowel diseases. Med Glas (Zenica). 2013;10:211-216.
7. Murata Y, Ishiguro Y, Itoh J, et al. The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J Gastroenterol. 1995;30(suppl 8):56-60.
8. Smith K. IBD: early use of anti-TNF agents might give a helping hand to paediatric patients with Crohn's disease. Nat Rev Gastroenterol Hepatol. 2013;10:691.
9. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11:243-255.
10. Taniguchi T, Ogasawara K, Takaoka A, et al. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;19:623-655.
11. Chen F, Song J, Di J, et al. IRF1 suppresses Ki-67 promoter activity through interfering with Sp1 activation. Tumour Biol. 2012;33: 2217-2225.
12. Yarilina A, Park-Min KH, Antoniv T, et al. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol. 2008;9:378-387.
13. Venkatesh D, Ernandez T, Rosetti F, et al. Endothelial TNF receptor 2 induces IRF1 transcription factor-dependent interferon-beta autocrine signaling to promote monocyte recruitment. Immunity. 2013;38:1025-1037.
14. Tada Y, Ho A, Matsuyama T, et al. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J Exp Med. 1997;185:231-238.
15. Mannick EE, Cote RL, Schurr JR, et al. Altered phenotype of dextran sulfate sodium colitis in interferon regulatory factor-1 knock-out mice. J Gastroenterol Hepatol. 2005;20:371-380.
16. Mudter J, Yu J, Zufferey C, et al. IRF4 regulates IL-17A promoter activity and controls RORgammat-dependent Th17 colitis in vivo. Inflamm Bowel Dis. 2011;17:1343-1358.
17. Huff CD, Witherspoon DJ, Zhang Y, et al. Crohn's disease and genetic hitchhiking at IBD5. Mol Biol Evol. 2012;29:101-111.
18. Senger DR, Asch BB, Smith BD, et al. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature. 1983;302:714-715.
19. Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055-1061.
20. Liaw L, Birk DE, Ballas CB, et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 1998;101:1468-1478.
21. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2001;276:46024-46030.
22. Miyazaki Y, Tashiro T, Higuchi Y, et al. Expression of osteopontin in a macrophage cell line and in transgenic mice with pulmonary fibrosis resulting from the lung expression of a tumor necrosis factor-alpha transgene. Ann N Y Acad Sci. 1995;760:334-341.
23. O'Regan AW, Hayden JM, Body S, et al. Abnormal pulmonary granuloma formation in osteopontin-deficient mice. Am J Respir Crit Care Med. 2001;164:2243-2247.
24. Yumoto K, Ishijima M, Rittling SR, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A. 2002;99:4556-4561.
25. Morales-Ibanez O, Dominguez M, Ki SH, et al. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology. 2013;58:1742-1756.
26. Chen F, Liu H, Shen Q, et al. Osteopontin: participation in inflammation or mucosal protection in inflammatory bowel diseases? Dig Dis Sci. 2013; 58:1569-1580.
27. da Silva AP, Ellen RP, Sorensen ES, et al. Osteopontin attenuation of dextran sulfate sodium-induced colitis in mice. Lab Invest. 2009;89: 1169-1181.
28. Sato T, Nakai T, Tamura N, et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut. 2005;54: 1254-1262.
29. Yu Q, Vazquez R, Khojeini EV, et al. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol. 2009;297:H76-H85.
30. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
31. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
32. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983-989.
33. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512.
34. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1:89-92.
35. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499-2507.
36. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
37. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535-542.
38. Samuel S, Bruining DH, Loftus EV Jr, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013;11:49-54. e1.
39. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-546.
40. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69: 238-249.
41. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94:513-521.
42. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol. 2004;26: 179-184.
43. Clavell M, Correa-Gracian H, Liu Z, et al. Detection of interferon regulatory factor-1 in lamina propria mononuclear cells in Crohn's disease. J Pediatr Gastroenterol Nutr. 2000;30:43-47.